Senolysis holds great promise for developing new therapeutics for cancers and age-related diseases

NewsGuard 100/100 Score

Announcing a new publication for Acta Materia Medica journal. The prevalence of age-related diseases has been progressively increasing worldwide.

The pathogenesis of these disorders, including cancer, is closely associated with an age-dependent decline in cellular functions. There are multiple layers of crosstalk between aging processes and oncogenesis. Therefore, a better understanding of the interplay between aging and cancer will facilitate the development of novel therapeutic intervention strategies for malignancies at advanced ages. Recent review articles have concisely summarized and updated aging and cancer hallmark features and adequately discussed the interplays at both the cellular and molecular levels. Because aging and cancer share several key mechanisms that define the hallmarks, targeting shared features, such as cellular senescence, may be beneficial for cancer prevention and treatments. Notably, senolysis, an innovative therapeutic intervention for selectively removing senescent cells, holds great promise for developing new therapeutic approaches for cancers and other age-related diseases, such as viral infections and cardiovascular diseases.

The authors of this article briefly summarize the recently updated knowledge on aging and cancer hallmarks, as well as the advances in senolysis for age-related conditions.

Source:
Journal reference:

Wang, J., et al. (2023) Aging and cancer hallmarks as therapeutic targets. Acta Materia Medica. doi.org/10.15212/AMM-2023-0018.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ketone supplement boosts efficacy of prostate cancer immunotherapy